Compare PXLW & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXLW | PRPO |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.0M | 44.4M |
| IPO Year | 2000 | 2000 |
| Metric | PXLW | PRPO |
|---|---|---|
| Price | $7.09 | $22.63 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $14.33 | N/A |
| AVG Volume (30 Days) | ★ 164.2K | 16.3K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.15 |
| EPS | ★ 12.46 | N/A |
| Revenue | $693,000.00 | ★ $24,049,000.00 |
| Revenue This Year | $47.19 | N/A |
| Revenue Next Year | $30.00 | N/A |
| P/E Ratio | $0.56 | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $4.84 | $10.52 |
| 52 Week High | $15.42 | $33.63 |
| Indicator | PXLW | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 59.11 | 35.80 |
| Support Level | $5.61 | $22.28 |
| Resistance Level | $7.45 | $26.16 |
| Average True Range (ATR) | 0.43 | 1.42 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 86.86 | 21.02 |
Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in Japan.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.